Chenbo Zeng, PhD

faculty photo
Research Assistant Professor of Radiology
Department: Radiology

Contact information
Department of Radiology
University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-746-2511
B.A. (Biochemistry)
Jilin University, Changchun, P.R. China, 1985.
M.S. (Biochemistry)
Jilin University, Changchun, P.R. China, 1988.
Ph.D (Biochemistry)
Iowa State University, Ames, Iowa, 1996.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Studying the biological functions of the sigma-2 receptor in breast cancer and in the central nervous system

Selected Publications

Sellmyer MA, Lee I, Hou C, Lieberman BP, Zeng C, Mankoff DA, Mach RH.: Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim. Mol Ther. 25(1): 120-126, 2017.

Chenbo Zeng and Robert H. Mach: The Evolution of the Sigma-2 Receptor from Obscure Binding Site to Bona Fide Therapeutic Target. Adv Exp Med Biol. Sigma Receptors: Their Role in Disease and as Therapeutic Targets. Sylvia B. Smith and Tsung-Ping Su (eds.). Springer, 964: 49-61, 2017.

Chenbo Zeng, Elizabeth S. McDonald, Robert H Mach: Molecular probes for imaging the sigma-2 receptor: in vitro and in vivo imaging studies Handb Exp Pharmacol. Sigma Proteins - Molecular pharmacology in physiology and pathophysiology. Felix J Kim Gavril Pasternak (eds.). Springer, 2017.

Elizabeth S. McDonald, Julia Mankoff, Mehran Makvandi, Wenhua Chu, Yunxiang Chu, Robert H Mach, Chenbo Zeng: Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells Biochemical and Biophysical Research Communications 486: 788-795 2017 Notes: Epub ahead of print.

Anderson RC, Makvandi M, Xu K, Lieberman BP, Zeng C, Pryma DA, Mach RH.: Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo. Nucl Med Biol. 43(12): 752-758, 2016.

Makvandi M, Xu K, Lieberman BP, Anderson RC, Effron SS, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH.: A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy. Cancer Res. 76(15): 4516-24, 2016.

Zeng C, Garg N, Mach RH.: The PGRMC1 Protein Level Correlates with the Binding Activity of a Sigma-2 Fluorescent Probe (SW120) in Rat Brain Cells. Mol Imaging Biol. 18: 172-9, 2016.

Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, Hou C, Lee H, Greenberg RA, Mankoff DA, Mach RH.: [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. Am J Nucl Med Mol Imaging. 6: 94-101, 2016.

Makvandi M, Tilahun ED, Lieberman BP, Anderson RC, Zeng C, Xu K, Hou C, McDonald ES, Pryma DA, Mach RH.: The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer. Biochem Biophys Res Commun 467: 1070-5, 2015

Elizabeth S. McDonald, Chenbo Zeng, David A Mankoff, Andrew Kossenkov, Robert H Mach: PGRMC1 expression is significantly up-regulated in triple negative breast cancer in vivo with associated activation of cyclin D1 target genes: Analysis of 1019 invasive breast cancers in the TCGA database. 2015 Annual Meeting American Association for Cancer Research 2015.

back to top
Last updated: 04/11/2017
The Trustees of the University of Pennsylvania